GtoPdb is requesting financial support from commercial users. Please see our sustainability page for more information.

acloproxalap   Click here for help

GtoPdb Ligand ID: 12097

Synonyms: Compound 5 [WO2020223685A1]
Compound class: Synthetic organic
Comment: We obtained the chemical structure for acloproxalap from the WHO's proposed INN list 127 (21 July 2022). In this document it was described as an anti-inflammatory. Acloproxalap is an analogue of reproxalap. Like its predecessor, acloproxalap was designed as a molecular trap for pro-inflammatory Reactive Aldehyde Species (RASP) molecules that are produced by metabolic and inflammatory processes, to treat diseases in which aldehyde toxicity is implicated in the pathogenesis [1]. We predict that acloproxalap is the INN for the clinical lead known as ADX-629.

acloproxalap is commercially available from our sponsors

2D Structure
Click here for help

2D Structure

An image of the ligand's 2D structure. For small molecules with SMILES these are drawn using the NCI/CADD Chemical Identifier Resolver. Click on the image to access the chemical structure search tool with the ligand pre-loaded in the structure editor. For other types of ligands, e.g. longer nucleotides and peptides, a manually drawn representation of the molecule may be provided.

✖
Click here for structure editor
Physico-chemical Properties
Click here for help

Physico-chemical Properties

Calculated molecular properties are available for small molecules and natural products (not peptides). Properties were generated using the Chemistry Development Kit (CDK) (Willighagen EL et al. Journal of Cheminformatics vol. 9:33. 2017, doi:10.1186/s13321-017-0220-4; https://cdk.github.io/). All properties were selected to enable the prediction of the Lipinski Rule-of-Five profile or ‘druglikeness’ for each ligand. For more info on each category see the help pages.

✖
Hydrogen bond acceptors 3
Hydrogen bond donors 2
Rotatable bonds 1
Topological polar surface area 59.14
Molecular weight 202.11
XLogP 1.65
No. Lipinski's rules broken 0

Generated using the Chemistry Development Kit (CDK) (Willighagen EL et al. Journal of Cheminformatics vol. 9:33. 2017, doi:10.1186/s13321-017-0220-4; https://cdk.github.io/)
SMILES / InChI / InChIKey
Click here for help

SMILES / InChI / InChIKey

SMILES (Simplified Molecular Input Line Entry Specification) A specification for unambiguously describing the structure of chemical molecules using short ASCII strings. Canonical SMILES specify a unique representation of the 2D structure without chiral or isotopic specifications. Isomeric SMILES include chiral specification and isotopes.

Standard InChI (IUPAC International Chemical Identifier) and InChIKey InChI is a non-proprietary, standard, textual identifier for chemical substances designed to facilitate linking of information and database searching. An InChIKey is a simplified version of a full InChI, designed for easier web searching.

Generated using the Chemistry Development Kit (CDK) (Willighagen EL et al. Journal of Cheminformatics vol. 9:33. 2017, doi:10.1186/s13321-017-0220-4; https://cdk.github.io/)

✖
Canonical SMILES Nc1cc2ccccc2nc1C(O)(C)C
Isomeric SMILES Nc1c(nc2ccccc2c1)C(C)(C)O
InChI InChI=1S/C12H14N2O/c1-12(2,15)11-9(13)7-8-5-3-4-6-10(8)14-11/h3-7,15H,13H2,1-2H3
InChI Key NOFRQDXKZDAYGB-UHFFFAOYSA-N

Generated using the Chemistry Development Kit (CDK) (Willighagen EL et al. Journal of Cheminformatics vol. 9:33. 2017, doi:10.1186/s13321-017-0220-4; https://cdk.github.io/)
No information available.
Summary of Clinical Use Click here for help
ADX-629 has been advanced to clinical evaluation in several inflammatory conditions, and a small phase 2 study has been completed in COVID-19 patients.
Clinical Trials
Clinical Trial ID Title Type Source Comment References
NCT05443685 ADX-629 Therapy for Sjogren-Larsson Syndrome Phase 1/Phase 2 Interventional University of Nebraska
NCT05392192 A Clinical Trial to Evaluate the Safety and Efficacy in Subjects With Chronic Cough Phase 2 Interventional Aldeyra Therapeutics, Inc.
NCT04908514 A Clinical Trial to Evaluate the Safety, Tolerability, and Efficacy of Subjects With Plaque Psoriasis Phase 2 Interventional Aldeyra Therapeutics, Inc.
NCT04728711 A Double Masked, Placebo Controlled, Single Center, Randomized Clinical Trial to Assess the Safety and Efficacy of Subjects With Mild Asthma Induced by the Bronchial Allergen Challenge (BAC) Phase 2 Interventional Aldeyra Therapeutics, Inc.
NCT04847544 A Randomized, Double-Blind, Placebo-Controlled, Clinical Trial to Evaluate the Safety, Tolerability, Efficacy, and Pharmacodynamics for the Treatment of COVID-19. Phase 2 Interventional Aldeyra Therapeutics, Inc.